PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $46.04 million. The enterprise value is $56.59 million.
Important Dates
The last earnings date was Friday, May 15, 2026, before market open.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 7.21 million shares outstanding. The number of shares has decreased by -62.56% in one year.
| Current Share Class | 7.21M |
| Shares Outstanding | 7.21M |
| Shares Change (YoY) | -62.56% |
| Shares Change (QoQ) | +76.58% |
| Owned by Insiders (%) | 20.29% |
| Owned by Institutions (%) | 2.19% |
| Float | 5.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 541.65 |
| Forward PS | 108.50 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 665.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.68.
| Current Ratio | 2.02 |
| Quick Ratio | 1.77 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,219.75 |
Financial Efficiency
Return on equity (ROE) is -67.22% and return on invested capital (ROIC) is -33.08%.
| Return on Equity (ROE) | -67.22% |
| Return on Assets (ROA) | -31.04% |
| Return on Invested Capital (ROIC) | -33.08% |
| Return on Capital Employed (ROCE) | -58.42% |
| Weighted Average Cost of Capital (WACC) | 5.71% |
| Revenue Per Employee | $2,073 |
| Profits Per Employee | -$694,073 |
| Employee Count | 41 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.20% in the last 52 weeks. The beta is 0.64, so PAVmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -66.20% |
| 50-Day Moving Average | 8.63 |
| 200-Day Moving Average | 10.58 |
| Relative Strength Index (RSI) | 33.71 |
| Average Volume (20 Days) | 15,327 |
Short Selling Information
The latest short interest is 17,722, so 0.25% of the outstanding shares have been sold short.
| Short Interest | 17,722 |
| Short Previous Month | 15,238 |
| Short % of Shares Out | 0.25% |
| Short % of Float | 0.34% |
| Short Ratio (days to cover) | 1.27 |
Income Statement
In the last 12 months, PAVmed had revenue of $85,000 and -$28.46 million in losses. Loss per share was -$29.95.
| Revenue | 85,000 |
| Gross Profit | -194,000 |
| Operating Income | -24.40M |
| Pretax Income | -22.16M |
| Net Income | -28.46M |
| EBITDA | -24.31M |
| EBIT | -24.40M |
| Loss Per Share | -$29.95 |
Full Income StatementBalance Sheet
The company has $6.46 million in cash and $17.01 million in debt, with a net cash position of -$10.55 million or -$1.46 per share.
| Cash & Cash Equivalents | 6.46M |
| Total Debt | 17.01M |
| Net Cash | -10.55M |
| Net Cash Per Share | -$1.46 |
| Equity (Book Value) | 24.99M |
| Book Value Per Share | 5.70 |
| Working Capital | 3.75M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.25 million and capital expenditures -$47,000, giving a free cash flow of -$6.29 million.
| Operating Cash Flow | -6.25M |
| Capital Expenditures | -47,000 |
| Depreciation & Amortization | 82,000 |
| Net Borrowing | 3.85M |
| Free Cash Flow | -6.29M |
| FCF Per Share | -$0.87 |
Full Cash Flow StatementMargins
| Gross Margin | -228.24% |
| Operating Margin | -28,700.00% |
| Pretax Margin | -26,065.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 62.56% |
| Shareholder Yield | 62.56% |
| Earnings Yield | -61.81% |
| FCF Yield | -13.67% |
Analyst Forecast
The average price target for PAVmed is $40.50, which is 533.80% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.50 |
| Price Target Difference | 533.80% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
